Status
Conditions
Treatments
About
The aim of this study is to determine the proportion of clinical improvement, the score changing of type 1 interferon selected gene expression, and analysis of transcriptomics profiling in patients with idiopathic uveitis positive IGRA before and after receiving Anti-Tuberculosis Therapy (ATT).
Hopefully, by conducting this research, we are able to provide valid data that demonstrate the advantages/disadvantages usage of Anti-Tuberculosis Therapy in patients with idiopathic uveitis IGRA positive that correlate with type I IFN. This research is a part of our efforts in discovering bio-marker candidates of idiopathic uveitis IGRA positive clinical patients who will benefit from the ATT administration.
Full description
Diagnostic of Idiopathic Uveitis IGRA Positive patients were still unclear. This situation happens because it is still can't be explained if the uveitis from the patients was caused by mycobacterium tuberculosis or not which leads to doubtfulness for Anti-Tuberculosis Treatment (ATT). This study aims to help to provide evidence on whether ATT usage for Idiopathic Uveitis IGRA Positive would bring beneficial impact for the patients. This study will try to analyze the data from clinical improvements, Type 1 Interferon changes, and transcriptomics analysis from the patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects who will be recruited to this study are patients who met the criteria described below:
Registered patients from September 2019 at Cipto Mangunkusumo Hospital
Idiopathic uveitis patients (proven having negative result by available etiological uveitis work-ups) with IGRA positive. IGRA positive value is defined by score above 0.35 u/ml obtained from Quantiferon Tuberculosis (QFT)-Gold Assay (QIAGEN).
Minimum age: 18 years old
Proven not having active Tuberculosis
Not previously received Anti Tuberculosis Therapy.
Not consuming antibiotic one to two weeks prior to the time of study
Not living together with Tuberculosis active patient
Not having plan to become pregnant during the time of study
Not part of reactive Tuberculosis risk group based on Latent Tuberculosis Incident WHO guidelines 2018
Active inflammation in the past 180 days characterized by the following sign based on SUN Criteria(in at least one eye)
Active inflammation during patient registration, characterized by the following sign based on SUN Criteria (in at least one eye)
Exclusion criteria
Note (^): Testing is conducted within 1-2 weeks prior to enrollment;
As many 10 subjects of the health volunteers are recruited for this study after giving consent. The health volunteers that will be recruited are the subject who met following criteria:
50 participants in 1 patient group
Loading...
Central trial contact
Rina La Distia Nora
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal